Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non-Small-Cell Lung Cancer and Synchronous Brain Metastases.
Ruchira V MahashabdeSajjad A BhattiBradley C MartinJacob T PainterAnaliz RodriguezJun YingChenghui LiPublished in: JCO oncology practice (2023)
Among older patients with NSCLC and SBM, first-line ICI use was associated with improved survival occurring 6 months after treatment initiation compared with chemotherapy only.